Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma by Jie Qian, Rongrong Chen, Ruiying Zhao, Yuchen Han, Yongfeng Yu

“…Compared with TCGA cohorts, our Chinese cohorts exhibited statistic differences in both somatic mutations and signaling pathways. We found that STK 11 alterations and TOP2A alterations were significantly associated with higher risk of recurrence in patients with LUSC.ConclusionsSignificant differences exist among three subtypes of LUSC in molecular characterizations.…”
Get full text

Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors by Alexandre Perrier, Audrey Didelot, Pierre Laurent-Puig, Hélène Blons, Simon Garinet

“…Moreover, in lung cancer, <i>EGFR</i> and <i>MET</i> mutations, oncogene fusions or <i>STK11</i> inactivating mutations were associated with low response rates. …”
Get full text

Genetic contribution of breast cancer genes in women of black African origin by Rokhaya Ndiaye, Jean Pascal Demba Diop, Ahmadou Dem, Alioune Dieye

“…While several genes have been associated with genetic predisposition (BRCA1, BRCA2, PALB2, TP53, PTEN, CDH1, STK11, ATM, CHEK2, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, … ), most studies have reported contribution of BRCA1 and BRCA2 pathogenic variants. …”
Get full text

Peutz–Jeghers Syndrome and the Role of Imaging: Pathophysiology, Diagnosis, and Associated Cancers by Sergio Klimkowski, Mohamed Ibrahim, Juan J. Ibarra Rovira, Mohamed Elshikh, Sanaz Javadi, Albert R. Klekers, Abdelraham A. Abusaif, Ahmed W. Moawad, Kamran Ali, Khaled M. Elsayes

“…The majority of cases are due to a mutation in the STK11 gene located at 19p13.3. The estimated incidence of PJS ranges from 1:50,000 to 1:200,000. …”
Get full text

Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report by Jin Sheng, MD, Weidong Han, MD, PhD, Hongming Pan, MD, PhD

“…Previous studies have suggested that SMARCA4-UT is often associated with smoking-related mutations, such as KRAS and STK11, rather than EGFR or ALK alterations. Nevertheless, no specific precision therapy has been identified for SMARCA4-UT. …”
Get full text

Analysis of candidate genes expected to be essential for melanoma surviving by Irina A. Krivosheeva, Alexandra Yu. Filatova, Sergei A. Moshkovskii, Ancha V. Baranova, Mikhail Yu. Skoblov

“…Here we present the results of transient siRNA-mediated knockdown of the four of such genes, namely, UNC45A, STK11IP, RHPN2 and ZNFX1, in melanoma cell line A375, then assayed the cells for their viability, proliferation and ability to migrate in vitro. …”
Get full text

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma by Sandra N. Freiberger, Patrick Turko, Martin Hüllner, Reinhard Dummer, Grégoire B. Morand, Mitchell P. Levesque, David Holzmann, Niels J. Rupp

“…While resistance mechanisms to immunotherapy in cutaneous melanoma have been uncovered, including alterations in <i>JAK1</i>/<i>2</i>, <i>B2M,</i> or <i>STK11</i>, a switch of oncogenic drivers under immunotherapy has not yet been observed. …”
Get full text

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression by Huiqiang Cai, Bin Zhang, Johanne Ahrenfeldt, Justin V. Joseph, Maria Riedel, Zongliang Gao, Sofie K. Thomsen, Ditte S. Christensen, Rasmus O. Bak, Henrik Hager, Mikkel H. Vendelbo, Xin Gao, Nicolai Birkbak, Martin K. Thomsen

“…Utilizing CRISPR-Cas9 in vivo, we target five potential tumor suppressor genes (Pten, Trp53, Rb1, Stk11, and RnaseL) in the mouse prostate, reaching humane endpoint after eight weeks without metastasis. …”
Get full text

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC by Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino, Anna Squadrilli, Gianpiero Fasola, Massimo Negrini, Marcello Tiseo, Manuela Ferracin, Andrea Ardizzoni

“…Results: The most frequently mutated genes were TP53 (49%), KRAS (43%), ERBB2 (13%), SMAD4 (13%), DDR2 (13%), STK11 (9%), ERBB4 (6%), EGFR (6%), BRAF (6%), and MET (6%). …”
Get full text

Undifferentiated embryonal sarcoma of the liver occurring in an adolescent: a case report with genomic analysis by Tomonari Shimagaki, Keishi Sugimachi, Yohei Mano, Emi Onishi, Yuki Tanaka, Rie Sugimoto, Kenichi Taguchi, Masaru Morita, Yasushi Toh

“…Genome analysis using FoundationOne CDx revealed 11 somatic mutations including TP53 (R196*) and STK11 (F354L). Adjuvant chemotherapy with ifosfamide and etoposide was performed, and the case has been followed up without recurrence for 1 year after hepatectomy. …”
Get full text

Health influenced by genetics: A first comprehensive analysis of breast cancer high and moderate penetrance susceptibility genes in the Tunisian population. by Maroua Boujemaa, Najah Mighri, Lotfi Chouchane, Mohamed Samir Boubaker, Sonia Abdelhak, Hamouda Boussen, Yosr Hamdi

“…We analyzed BRCA1/2, PTEN, STK11, TP53, ATM, BRIP1, CHEK2 and PALB2 genotype data obtained from 135 healthy participants genotyped using Affymetrix Genome-Wide Human SNP-Array 6.0. …”
Get full text

Influence of retroelements on oncogenes and tumor suppressors in carcinogenesis: A review by Rustam N. Mustafin

“…APC, NF1, MSH2, PTEN, RB1, TSC2, STK11, VHL) and inactivate them, which is associated with the presence of hot spots of insertional mutagenesis in them. …”
Get full text

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine de... by Weijing Cai, Dapeng Zhou, Weibo Wu, Wen Ling Tan, Jiaqian Wang, Caicun Zhou, Yanyan Lou

“…The most commonly mutated genes with predicted neo-antigens are KRAS, TTN, RYR2, MUC16, TP53, USH2A, ZFHX4, KEAP1, STK11, FAT3, NAV3 and EGFR. Conclusions Our results support the feasibility of discovering individualized HLA Class II presented mutant peptides as candidates for immunodiagnosis and immunotherapy of lung adenocarcinoma.…”
Get full text

Molecular Profiling of Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma and Cutaneous Melanoma by Attila Mokánszki, Gábor Méhes, Szilvia Lilla Csoma, Sándor Kollár, Yi-Che Chang Chien

“…In MCPyV-positive melanoma cases, besides <i>BRAF</i> mutations the following genes were also affected: <i>PIK3CA</i>, <i>STK11</i>, <i>CDKN2A</i>, <i>SMAD4</i>, and <i>APC</i>. …”
Get full text

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC by Fan Zhang, Jinliang Wang, Yu Xu, Shangli Cai, Tao Li, Guoqiang Wang, Chengcheng Li, Lei Zhao, Yi Hu

“…Particularly in nonsquamous NSCLC, KRAS mutation remarkably interacted with its co-occurring mutations in TP53, STK11, PTPRD, RBM10, and ATM. Based on single mutation-based prediction models, adding interaction terms (referred to as inter-model) improved discriminative utilities in both training and validation sets. …”
Get full text

Disease spectrum of gastric cancer susceptibility genes by McKinley, Sophia K, Singh, Preeti, Yin, Kanhua, Wang, Jin, Zhou, Jingan, Bao, Yujia, Wu, Menghua, Pathak, Kush, Mullen, John T, Braun, Danielle, Hughes, Kevin S

“…Out of 27 candidate genes, 13 were identified as gastric cancer susceptibility genes (APC, ATM, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH-Biallelic, PALB2, SMAD4, and STK11). A total of 145 gene–disease associations (with 45 unique diseases) were found to be associated with these 13 genes. …”
Get full text

Disease spectrum of gastric cancer susceptibility genes by McKinley, Sophia K, Singh, Preeti, Yin, Kanhua, Wang, Jin, Zhou, Jingan, Bao, Yujia, Wu, Menghua, Pathak, Kush, Mullen, John T, Braun, Danielle, Hughes, Kevin S

“…Out of 27 candidate genes, 13 were identified as gastric cancer susceptibility genes (APC, ATM, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH-Biallelic, PALB2, SMAD4, and STK11). A total of 145 gene–disease associations (with 45 unique diseases) were found to be associated with these 13 genes. …”
Get full text

Germline variant testing in serrated polyposis syndrome by Murphy, A, Solomons, J, Risby, P, Gabriel, J, Bedenham, T, Johnson, M, Atkinson, N, Bailey, AA, Bird-Lieberman, E, Leedham, SJ, East, JE, Biswas, S

“…The majority were tested for a hereditary colorectal cancer panel including MUTYH, APC, PTEN, SMAD4, BMPR1A, STK11, NTLH1, POLD1, POLE, GREM1 (40-kb duplication), PMS2, and Lynch syndrome mismatch repair genes.…”

Daily Practice Assessment of <i>KRAS</i> Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner by Christophe Bontoux, Véronique Hofman, Patrick Brest, Marius Ilié, Baharia Mograbi, Paul Hofman

“…In parallel, other studies have shown that NSCLC harboring co-mutations in <i>KRAS</i> and <i>STK11</i> or <i>KEAP1</i> have demonstrated primary resistance to immune checkpoint inhibitors. …”
Get full text

Lung Cancer Management with Silibinin: A Historical and Translational Perspective by Sara Verdura, Elisabet Cuyàs, Verónica Ruiz-Torres, Vicente Micol, Jorge Joven, Joaquim Bosch-Barrera, Javier A. Menendez

“…Finally, by unraveling the selective vulnerability of silibinin-treated tumor cells to drugs using CRISPR-based chemosensitivity screenings (e.g., the hexosamine biosynthesis pathway inhibitor azaserine), we illustrate how the therapeutic use of silibinin against targetable weaknesses might be capitalized in specific lung cancer subtypes (e.g., <i>KRAS/STK11</i> co-mutant tumors). Forthcoming studies should take up the challenge of developing silibinin and/or next-generation silibinin derivatives as novel lung cancer-preventive and therapeutic biomolecules.…”
Get full text